NEW YORK, Sept. 04, 2015 (GLOBE NEWSWIRE) -- Stull, Stull & Brody ("SS&B") announces that a class action lawsuit was commenced in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. (“Northwest Biotherapeutics” or the “Company”) (NASDAQ:NWBO) between March 8, 2013 and August 20, 2015 (the "Class Period").
If you purchased Northwest Biotherapeutics securities during the Class Period you may move the Court to serve as lead plaintiff in the action by October 26, 2015.
The Complaint alleges that throughout the Class Period defendants concealed that: (1) claims regarding positive results from the DCVax-Direct Trial (the “Results”) were based on preliminary and unconfirmed trial results; (2) the Results had not been reviewed or analyzed by the hospitals conducting the trials; (3) the Company’s statements about the Results were derived from patient case report forms sent to the Company only because it sponsored the study; (4) the Company was the subject of an aggressive stock promotion campaign including promoters using false identities and credentials; (5) German regulators required additional information from the Company in order for the Company’s DCVax-L Trial to continue uninterrupted; and (6) as a result of the above, the Company’s financial statements were materially false and misleading.
SS&B is also investigating whether allegations in news reports that Northwest Biotherapeutics has used undisclosed, paid stock promoters to increase the value of its shares, which SS&B believes may have been a waste of corporate assets that exposed the Company to liability.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Michael J. Klein, Esq. of SS&B by e-mail at NWBO@ssbny.com, by calling 1-800-337-4983 x147, by fax at 212/490-2022, or by writing to Stull, Stull & Brody, 6 East 45th Street, New York, NY 10017. You can also visit our website at www.ssbny.com.
SS&B has litigated many class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. The SS&B website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.